(MENAFN- PR Newswire)
First and only device using non-invasive ultrasound pulses to facilitate passage of kidney stone fragments post-lithotripsy
Kidney stones affect one in 10 people in the US, costing $10 billion annually1
SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- SonoMotion, a medical device company developing non-invasive solutions for kidney stones, announced today that the FDA has granted de novo clearance for the Company's Stone ClearTM device for the anesthesia-free treatment of post-lithotripsy kidney stone fragments. Stone Clear is the first and only device that delivers ultrasound pulses externally to move and facilitate the passage of residual fragments without surgery and in the clinic setting.
Continue Reading
SonoMotion's Stone Clear is the first and only FDA-cleared device using non-invasive ultrasound pulses to facilitate passage of kidney stone fragments post-lithotripsy without surgery and in any health care setting.
"Patients with post-lithotripsy residual fragments are more likely to have complications, emergency department visits, or repeat procedures, yet they have no reliable non-invasive option aside from passive observation," said James E. Lingeman, MD,
Clinical Professor of Urology, Indiana University School of Medicine. "The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake."
The Stone Clear device is part of a platform designed to treat kidney stones without requiring anesthesia and in any health care settings where a patient with a kidney stone may present themselves, including the doctor's office and emergency departments. Ultrasound propulsion in patients with post-lithotripsy residual fragments reduced the risk of relapse by 70% compared to standard-of-care observation.2 Results from the randomized controlled clinical trial with up to five-year follow-up are published in the December 2024 issue of the Journal of Urology .
SonoMotion's second solution, called Break WaveTM, will operate on the same platform and will use focused ultrasound to non-invasively fragment kidney stones in the upper urinary tract without anesthesia and in a clinic setting. Break Wave is currently undergoing clinical trials in the United States and Canada.
"SonoMotion's goal is to fundamentally change how kidney stones are treated, and securing FDA clearance for Stone Clear is a major milestone towards this goal," commented Oren Levy, PhD, Co-Founder and Chief Executive Officer, SonoMotion. "SonoMotion's technologies have the potential to be a first-line treatment for kidney stones, offering a solution for patients who want to avoid anesthesia, minimize wait times for surgery without the need for urinary stenting – a procedure often more painful than the kidney stone itself."
ABOUT SONOMOTION
SonoMotion, a VC-backed startup based in San Mateo, CA, is a clinical stage medical technology company developing next generation non-invasive solutions for the treatment of kidney stones. The SonoMotion Break Wave device is an investigational device that is not approved for sale in the U.S. or anywhere in the world. To learn more, please visit
.
References:
Litwin MS, CS S. NIH Publication No. 12-7865.
Sorensen MD
et al. Randomized Controlled Trial of Ultrasonic Propulsion–Facilitated Clearance of Residual Kidney Stone Fragments vs Observation. Journal of Urology. 2024 Dec 1;212(6):811–20.
SOURCE SonoMotion, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN13112024003732001241ID1108882084
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.